<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04836169</url>
  </required_header>
  <id_info>
    <org_study_id>InCaveoDanielandDaniel2021</org_study_id>
    <nct_id>NCT04836169</nct_id>
  </id_info>
  <brief_title>Phase 1: Randomized Evaluation of a System to Deliver Mobile Cognitive Behavioral Therapy</brief_title>
  <acronym>P1RESPECT</acronym>
  <official_title>Phase 1: Randomized Evaluation of a System to Deliver Mobile Cognitive Behavioral Therapy to Lower Pain Catastrophizing Scores</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InCaveo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InCaveo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical study described in this Clinical Investigation Plan (CIP) will be completed in&#xD;
      two stages, Phase I and Phase II. The results of Phase I will confirm patient use of&#xD;
      InCaveo's EOA system with integrated mobile CBT but without tapering to improve The Pain&#xD;
      Catastrophizing Scale (PCS) scores, and secondarily scores on the VNS pain scale, the Tampa&#xD;
      Scale of Kinesiophobia (TSK), and patient satisfaction scores in the subacute period (defined&#xD;
      as 2 weeks to 3 months post TKR). Statistically significant positive results on the Pain&#xD;
      Catastrophizing Scale (PCS) will trigger phase 2. Phase 1 will also inform the detailed&#xD;
      conditions and patient management algorithms for Phase II.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The InCaveo End Opioid Addiction (EOA) System is an integrated pain management therapeutic&#xD;
      and opioid tapering system providing alternate treatment options via self-service Cognitive&#xD;
      Behavior Therapy (CBT) built into a mobile software app, patient medication usage, and&#xD;
      tracking of patient PROs. It is designed to be used alongside Usual Standard of Care using&#xD;
      Pill Bottles or to simplify, Usual Care with Pill Bottles (UCPB) treatment practices. The&#xD;
      InCaveo EOA System is designed to improve a set of patient outcome measures, primarily Pain&#xD;
      Catastrophizing Scale (PCS) and secondarily the Visual Numeric Pain (VNS), Kinesiophobia&#xD;
      (TSK) and satisfaction scores while facilitating the ability of patients to taper off their&#xD;
      pain medication faster than through the use of USPB in the management of post-operative pain.&#xD;
      In order to reduce confounding variables, the study will focus on pain management following a&#xD;
      single surgical procedure: Total Knee Replacement (TKR) surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized parallel-group</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Catastrophizing Scale (PCS)</measure>
    <time_frame>60 days</time_frame>
    <description>A measure of the extent of catastrophizing</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Analgesics, Opioid</condition>
  <arm_group>
    <arm_group_label>InCaveo EOA System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>InCaveo EOA System (including integrated CBT but without tapering) group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group-usual care with pill bottles</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>UCPB group-usual care with pill bottles</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>InCaveo's EOA system with integrated mobile CBT</intervention_name>
    <description>integrated pain management therapeutic and tapering system including a software apt that manages and tracks patient-reported outcomes, including pain levels, medication use, quality of life</description>
    <arm_group_label>InCaveo EOA System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient has a Pain Catastrophizing Score &gt;16&#xD;
&#xD;
          2. 55 years of age and older.&#xD;
&#xD;
          3. English speaking.&#xD;
&#xD;
          4. Has a smartphone (iPhone).&#xD;
&#xD;
          5. Able to swallow oral medications.&#xD;
&#xD;
          6. No continuous daily opioid as defined as more than 15 days in the 30 days before&#xD;
             surgery.&#xD;
&#xD;
          7. Undergoing TKR surgery.&#xD;
&#xD;
          8. Patients who are willing and able to comply with scheduled visits and study&#xD;
             procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with Opioid Use Disorder (OUD).&#xD;
&#xD;
          2. Actively using illicit drugs.&#xD;
&#xD;
          3. Allergy to opioids&#xD;
&#xD;
          4. Older than 85 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hoyman Hong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>InCaveo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cynthia Harris, BS</last_name>
    <phone>8326776747</phone>
    <email>cindy@clinregconsult.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael A Daniel, MBA</last_name>
    <phone>4154070223</phone>
    <email>madaniel@clinregconsult.com</email>
  </overall_contact_backup>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 5, 2021</study_first_submitted>
  <study_first_submitted_qc>April 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

